CHM.AU CHIMERIC THERAPEUTICS LTD
Not Yet Opened 11-05 16:12:00 AEDT
0.01
+0.00
+20.00%
High
0.01
Low
0.01
Vol
13.87M
Open
0.01
D1 Closing
0.01
Amplitude
30.00%
Mkt Cap
11.70M
Tradable Cap
9.36M
Total Shares
975.14M
T/O
153.90K
T/O Rate
1.78%
Tradable Shares
780.00M
P/B
--
ROE
--
EPS
0.00
52wk High
--
52wk Low
--
P/E
--
Dividend
--
Div.Yield
--
ROA
--
Time
5D
D
W
M
News
New Post(s)
Profile
BRIEF-Chimeric Therapeutics Announces A$5 Million Placement
Reuters · 10-21
BRIEF-Chimeric Therapeutics Announces A$5 Million Placement
Chimeric Therapeutics Ltd-$5 Million Placement to Progress Chm Cdh17 Trial
THOMSON REUTERS · 10-21
Chimeric Therapeutics Ltd-$5 Million Placement to Progress Chm Cdh17 Trial
Chimeric Therapeutics - Executive Chairman Paul Hopper to Participate With a$1 Mln Investment
THOMSON REUTERS · 10-21
Chimeric Therapeutics - Executive Chairman Paul Hopper to Participate With a$1 Mln Investment
Chimeric Therapeutics - Placement at an Issue Price of a$0.008 per New Fully Paid Ordinary Share
THOMSON REUTERS · 10-21
Chimeric Therapeutics - Placement at an Issue Price of a$0.008 per New Fully Paid Ordinary Share
Leukaemia patient shows complete response in Chimeric Therapeutics’ latest trial
The Market Herald · 10-07
Leukaemia patient shows complete response in Chimeric Therapeutics’ latest trial
Failure to report prompts ASX to impose multiple company suspensions
The Market Herald · 10-01
Failure to report prompts ASX to impose multiple company suspensions
University of Pennsylvania Joins Chimeric Therapeutics' Cell Therapy Clinical Trial; Shares Up 7%
MT Newswires Live · 09-11
University of Pennsylvania Joins Chimeric Therapeutics' Cell Therapy Clinical Trial; Shares Up 7%
University of Pennsylvania Joins Chimeric Therapeutics' Cell Therapy Clinical Trial; Shares Up 7%
MT Newswires Live · 09-11
University of Pennsylvania Joins Chimeric Therapeutics' Cell Therapy Clinical Trial; Shares Up 7%
BUZZ-Australia's Chimeric Therapeutics gains as FY loss narrows
Reuters · 08-30
BUZZ-Australia's Chimeric Therapeutics gains as FY loss narrows
BRIEF-Chimeric Therapeutics Posts Net Loss For Year Attributable A$12.5 Mln
Reuters · 08-30
BRIEF-Chimeric Therapeutics Posts Net Loss For Year Attributable A$12.5 Mln
Chimeric Therapeutics Doses First Patient in Gastrointestinal Cancer Drug Trial
MT Newswires Live · 08-28
Chimeric Therapeutics Doses First Patient in Gastrointestinal Cancer Drug Trial
Chimeric Therapeutics Concludes GMP Manufacturing for CHM CDH17 CAR-T Trial
MT Newswires Live · 08-16
Chimeric Therapeutics Concludes GMP Manufacturing for CHM CDH17 CAR-T Trial
Chimeric Therapeutics Concludes GMP Manufacturing for CHM CDH17 CAR-T Trial
MT Newswires Live · 08-16
Chimeric Therapeutics Concludes GMP Manufacturing for CHM CDH17 CAR-T Trial
Chimeric Therapeutics Partners with Cell Therapies for CAR T Manufacturing in Australia; Shares Jump 13%
MT Newswires Live · 08-09
Chimeric Therapeutics Partners with Cell Therapies for CAR T Manufacturing in Australia; Shares Jump 13%
Chimeric Therapeutics Partners with Cell Therapies for CAR T Manufacturing in Australia; Shares Jump 13%
MT Newswires Live · 08-09
Chimeric Therapeutics Partners with Cell Therapies for CAR T Manufacturing in Australia; Shares Jump 13%
BRIEF-Chimeric Therapeutics Says Partnering With Cell Therapies Australia
Reuters · 08-09
BRIEF-Chimeric Therapeutics Says Partnering With Cell Therapies Australia
Chimeric Partnering With Cell Therapies Australia-Chm.ax
THOMSON REUTERS · 08-09
Chimeric Partnering With Cell Therapies Australia-Chm.ax
Chimeric Therapeutics Recruits First Patient in Cell Therapy Cancer Trial; Shares Rally 16%
MT Newswires Live · 07-22
Chimeric Therapeutics Recruits First Patient in Cell Therapy Cancer Trial; Shares Rally 16%
Chimeric Therapeutics Recruits First Patient in Cell Therapy Cancer Trial; Shares Rally 16%
MT Newswires Live · 07-22
Chimeric Therapeutics Recruits First Patient in Cell Therapy Cancer Trial; Shares Rally 16%
BUZZ-Australia Chimeric Therapeutics rises on first enrolment in cancer cell therapy trial
Reuters · 07-22
BUZZ-Australia Chimeric Therapeutics rises on first enrolment in cancer cell therapy trial
Load more
Introduction
Company Name.
CHIMERIC THERAPEUTICS LTD
Affiliated Markets:
ASX
Listing Date:
--
Main Business:
Issue price:
--
{"stockData":{"symbol":"CHM.AU","market":"AU","secType":"STK","nameCN":"CHIMERIC THERAPEUTICS LTD","latestPrice":0.012,"timestamp":1730783520000,"preClose":0.01,"halted":0,"volume":13870948,"delay":0,"nameEN":"CHIMERIC THERAPEUTICS LTD","floatShares":779995592,"shares":975140820,"eps":-0.018011,"marketStatus":"Not Yet Opened","change":0.002,"latestTime":"11-05 16:12:00 AEDT","open":0.01,"high":0.013,"low":0.01,"amount":153901,"amplitude":0.3,"askPrice":0.012,"askSize":1224999,"bidPrice":0.011,"bidSize":128195,"shortable":3,"etf":0,"ttmEps":-0.018011,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":0,"beginTime":1730847600000},"marketStatusCode":0,"adr":0,"exchange":"ASX","adjPreClose":0.01,"openAndCloseTimeList":[[1730761200000,1730782800000]],"volumeRatio":4.617157,"lotSize":1,"tradeCurrency":"AUD"},"requestUrl":"/m/hq/s/CHM.AU","defaultTab":"news","newsList":[{"id":"2477044044","title":"BRIEF-Chimeric Therapeutics Announces A$5 Million Placement","url":"https://stock-news.laohu8.com/highlight/detail?id=2477044044","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2477044044?lang=en_us&edition=fundamental","pubTime":"2024-10-21 08:50","pubTimestamp":1729471847,"startTime":"0","endTime":"0","summary":"Oct 21 - Chimeric Therapeutics Ltd : * A$5 MILLION PLACEMENT TO PROGRESS CHM CDH17 TRIAL * PLACEMENT AT AN ISSUE PRICE OF A$0.008 PER NEW FULLY PAID ORDINARY SHARE * EXECUTIVE CHAIRMAN PAUL HOPPER TO PARTICIPATE WITH A$1 MILLION INVESTMENTFurther company coverage: ","market":null,"thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7067","CHM.AU"],"gpt_icon":0},{"id":"2477156044","title":"Chimeric Therapeutics Ltd-$5 Million Placement to Progress Chm Cdh17 Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2477156044","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2477156044?lang=en_us&edition=fundamental","pubTime":"2024-10-21 08:48","pubTimestamp":1729471734,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241021:nTUE1B5W5Z:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["CHM.AU","BK7067"],"gpt_icon":0},{"id":"2477044469","title":"Chimeric Therapeutics - Executive Chairman Paul Hopper to Participate With a$1 Mln Investment","url":"https://stock-news.laohu8.com/highlight/detail?id=2477044469","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2477044469?lang=en_us&edition=fundamental","pubTime":"2024-10-21 08:48","pubTimestamp":1729471734,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241021:nTUE1B5W5Z:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["CHM.AU","BK7067"],"gpt_icon":0},{"id":"2477044468","title":"Chimeric Therapeutics - Placement at an Issue Price of a$0.008 per New Fully Paid Ordinary Share","url":"https://stock-news.laohu8.com/highlight/detail?id=2477044468","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2477044468?lang=en_us&edition=fundamental","pubTime":"2024-10-21 08:48","pubTimestamp":1729471734,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241021:nTUE1B5W5Z:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7067","CHM.AU"],"gpt_icon":0},{"id":"2473119500","title":"Leukaemia patient shows complete response in Chimeric Therapeutics’ latest trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2473119500","media":"The Market Herald","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2473119500?lang=en_us&edition=fundamental","pubTime":"2024-10-07 08:17","pubTimestamp":1728260220,"startTime":"0","endTime":"0","summary":"Chimeric Therapeutics has reported one leukaemia patient has shown a complete response in its latest drug trial – in other words, for now, that patient is cancer-free.This latest breakthrough – which could bode well for Chimeric shareholders, given the stock is currently suspended – comes on the back of a trial using a combination of ‘CORE-NK‘ and Vactosertib in advanced cancer patients.‘CORE-NK’ takes its name from Natural Killer cells which “are part of our innate immune system,” according to the company’s website. A previous trial found more success combining it with Vactosertib.This is the first round of trials to ever mix that drug with NK cell treatments; the trial is being undertaken at the UH Seidman Cancer Center in Ohio, USA.“We are very happy to report that one study subject with advanced Acute Myelogenous Leukemia experienced a Complete Response at Day 28 after starting treatment with the CHM CORE- NK + Vactosertib combination,” Chimeric COO Dr. Rebecca McQualter said.Jo","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://themarketonline.com.au/leukaemia-patient-shows-complete-response-in-chimeric-therapeutics-latest-trial-2024-10-07/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"markerherald_stock","symbols":["BK4139","LENZ","BK7067","CHM.AU","BK7504","BK7095","AML.AU"],"gpt_icon":0},{"id":"2472315043","title":"Failure to report prompts ASX to impose multiple company suspensions","url":"https://stock-news.laohu8.com/highlight/detail?id=2472315043","media":"The Market Herald","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2472315043?lang=en_us&edition=fundamental","pubTime":"2024-10-01 12:53","pubTimestamp":1727758380,"startTime":"0","endTime":"0","summary":"The ASX today informed more than 20 companies – across numerous sectors, including healthcare, technology and basic materials – that they would be suspended from trading as a result failure provide periodic reports by the correct date.Tech stocks included in the suspension were Bluechiip Ltd , Vection Technologies Ltd , and Vinyl Group Ltd – with this coming only one day after the latter company informed investors it has snaffled a takeover of UK-based music platform Serenade.In communication services, there was Sportshero Ltd , while healthcare was represented by Chimeric Therapeutics Ltd .The consumer cyclical sector saw two companies suspended Site Group International Ltd and Sprintex Ltd , while consumer defensive had three: Prestal Holdings Ltd , Wide Open Agriculture , and Yowie Group Ltd .It added that if the report in question was lodged between the closure of the market announcements office on Monday and the suspension being imposed, securities would be reinstated the tradi","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://themarketonline.com.au/failure-to-report-prompts-asx-to-impose-multiple-company-suspensions-2024-10-01/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"markerherald_stock","symbols":["VR1.AU","CHM.AU","BK7506","VNL.AU","RLC.AU","EDE.AU","SIX.AU","EUR.AU","BCT.AU","NRZ.AU","BK7016","NWF.AU","BK7142","BK7095","BK7009","THR.AU","WOA.AU","SIT.AU","BK7132","BK7067","CLZ.AU","BK7083","DGR.AU","BK7011","BK7117","BK7104","BK7141","BK7504","BK7116","BK7509","BK7505","BK7036","TAS.AU","FGR.AU","SVG.AU","YOW.AU","FGH.AU","PH2.AU","BK7076","IDA.AU","IEC.AU","PTL.AU","WBE.AU","SHO.AU","BK7020","BK7051"],"gpt_icon":0},{"id":"2466489094","title":"University of Pennsylvania Joins Chimeric Therapeutics' Cell Therapy Clinical Trial; Shares Up 7%","url":"https://stock-news.laohu8.com/highlight/detail?id=2466489094","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2466489094?lang=en_us&edition=fundamental","pubTime":"2024-09-11 09:26","pubTimestamp":1726018012,"startTime":"0","endTime":"0","summary":"Chimeric Therapeutics partnered with the University of Pennsylvania to enroll patients in the Phase 1/2 clinical trial for CHM CDH17 cell therapy in patients with advanced colorectal and gastric cancer, and intestinal neuroendocrine tumors, according to a Wednesday filing with the Australian Securities Exchange.The trial is a two-stage study aimed at determining the recommended phase 2 dose of CHM CDH17, assessing its safety and objective response rate, the filing said.Additional trial sites are expected to open for enrollment in the second half of the year.Shares rose nearly 7% in morning trade.Price : $0.02, Change: $+0.0010, Percent Change: +6.67%","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4139","AUD","LENZ","BK7067","CHM.AU","BK4125"],"gpt_icon":0},{"id":"2466448596","title":"University of Pennsylvania Joins Chimeric Therapeutics' Cell Therapy Clinical Trial; Shares Up 7%","url":"https://stock-news.laohu8.com/highlight/detail?id=2466448596","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2466448596?lang=en_us&edition=fundamental","pubTime":"2024-09-11 09:26","pubTimestamp":1726018012,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_live","symbols":["BK7067","BK4125","XAO.AU","XJO.AU","LENZ","CHM.AU","XKO.AU","AUD","BK4139"],"gpt_icon":0},{"id":"2463278030","title":"BUZZ-Australia's Chimeric Therapeutics gains as FY loss narrows","url":"https://stock-news.laohu8.com/highlight/detail?id=2463278030","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2463278030?lang=en_us&edition=fundamental","pubTime":"2024-08-30 12:45","pubTimestamp":1724993136,"startTime":"0","endTime":"0","summary":"** Shares of Chimeric Therapeutics rise as much as 18.8% to A$0.019, their highest levels since Aug 16 ** The biotech firm posts FY loss of A$12.5 mln , compared with a loss of A$25.9 mln ** Co says decreased loss largely relates to scale-down of headcount, reduction of general administration expenses and reprioritisation of projects ** About 2.1 mln shares change hands, 1.8 times the 30-day average volume of shares ** Stock has fallen 54.2% this year, as of last close ","market":null,"thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["XAO.AU","BK7067","XJO.AU","XKO.AU","CHM.AU"],"gpt_icon":0},{"id":"2463247853","title":"BRIEF-Chimeric Therapeutics Posts Net Loss For Year Attributable A$12.5 Mln","url":"https://stock-news.laohu8.com/highlight/detail?id=2463247853","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2463247853?lang=en_us&edition=fundamental","pubTime":"2024-08-30 09:42","pubTimestamp":1724982146,"startTime":"0","endTime":"0","summary":"Aug 30 (Reuters) - Chimeric Therapeutics Ltd : * NET LOSS FOR YEAR ATTRIBUTABLE A$12.5 MILLIONSource text for Eikon: Further company coverage: ((Reuters.Briefs@thomsonreuters.com;))","market":null,"thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CHM.AU","BK7067"],"gpt_icon":0},{"id":"2462805458","title":"Chimeric Therapeutics Doses First Patient in Gastrointestinal Cancer Drug Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2462805458","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2462805458?lang=en_us&edition=fundamental","pubTime":"2024-08-28 18:46","pubTimestamp":1724841971,"startTime":"0","endTime":"0","summary":"Chimeric Therapeutics dosed the first patient in its first-in-human trial of CHM CDH17, a treatment for advanced colorectal, gastric, and intestinal neuroendocrine cancers, the clinical stage cell therapy company said Wednesday.The first patient was dosed at Sarah Cannon Research Institute in Tennessee's Nashville.The Phase 1/2 trial, which is a two-stage study, aims to establish a recommended dose for Phase 2 and assess the safety and response rate of the therapy, the filing said.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["CHM.AU","LENZ","BK4139","BK7067"],"gpt_icon":0},{"id":"2459808962","title":"Chimeric Therapeutics Concludes GMP Manufacturing for CHM CDH17 CAR-T Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2459808962","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2459808962?lang=en_us&edition=fundamental","pubTime":"2024-08-16 08:09","pubTimestamp":1723766944,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_live","symbols":["XJO.AU","CHM.AU","XKO.AU","BK4139","XAO.AU","LENZ","CAR","BK7067"],"gpt_icon":0},{"id":"2459803842","title":"Chimeric Therapeutics Concludes GMP Manufacturing for CHM CDH17 CAR-T Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2459803842","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2459803842?lang=en_us&edition=fundamental","pubTime":"2024-08-16 08:09","pubTimestamp":1723766944,"startTime":"0","endTime":"0","summary":"Clinical stage cell therapy company Chimeric Therapeutics completed Good Manufacturing Practice manufacturing for its CHM CDH17 CAR-T trial, according to a Friday filing with the Australian bourse.CHM CDH17 is cell therapy in patients with advanced gastrointestinal cancers.Cells from the first clinical participant, collected at Nashville's Sarah Cannon Cancer Centre, were processed and passed all quality checks. They are now en route back to the trial site for infusion, the filing said.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4022","CHM.AU","BK4139","CAR","BK7067","LENZ","BK4230"],"gpt_icon":0},{"id":"2458585218","title":"Chimeric Therapeutics Partners with Cell Therapies for CAR T Manufacturing in Australia; Shares Jump 13%","url":"https://stock-news.laohu8.com/highlight/detail?id=2458585218","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2458585218?lang=en_us&edition=fundamental","pubTime":"2024-08-09 11:23","pubTimestamp":1723173795,"startTime":"0","endTime":"0","summary":"Chimeric Therapeutics entered a collaboration with domestic commercial contract development and manufacturing firm Cell Therapies to look into the possibility of manufacturing Chimeric's CAR T assets in Australia, according to a Friday filing with the Australian bourse.Cell Therapies specializes in cell therapy, gene therapy, regenerative medicine, and cellular immunotherapy products.Shares of Chimeric Therapeutics jumped nearly 13% in recent trade.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7067","CAR","BK4139","CHM.AU","XKO.AU","XAO.AU","XJO.AU","LENZ"],"gpt_icon":0},{"id":"2458506586","title":"Chimeric Therapeutics Partners with Cell Therapies for CAR T Manufacturing in Australia; Shares Jump 13%","url":"https://stock-news.laohu8.com/highlight/detail?id=2458506586","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2458506586?lang=en_us&edition=fundamental","pubTime":"2024-08-09 11:23","pubTimestamp":1723173795,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_live","symbols":["BK7067","XAO.AU","CAR","LENZ","XKO.AU","BK4139","CHM.AU","XJO.AU"],"gpt_icon":0},{"id":"2458309595","title":"BRIEF-Chimeric Therapeutics Says Partnering With Cell Therapies Australia","url":"https://stock-news.laohu8.com/highlight/detail?id=2458309595","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2458309595?lang=en_us&edition=fundamental","pubTime":"2024-08-09 09:19","pubTimestamp":1723166371,"startTime":"0","endTime":"0","summary":"Aug 9 (Reuters) - Chimeric Therapeutics Ltd : * CHIMERIC PARTNERING WITH CELL THERAPIES AUSTRALIA * COLLABORATION WITH CELL THERAPIES TO EXPLORE POTENTIAL TO MANUFACTURE CHIMERIC'S CAR T ASSETS IN AUSTRALIA Further company coverage: ((Reuters.Briefs@thomsonreuters.com;))","market":null,"thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["XJO.AU","BK7067","CHM.AU","XAO.AU","XKO.AU"],"gpt_icon":0},{"id":"2458372474","title":"Chimeric Partnering With Cell Therapies Australia-Chm.ax","url":"https://stock-news.laohu8.com/highlight/detail?id=2458372474","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2458372474?lang=en_us&edition=fundamental","pubTime":"2024-08-09 07:06","pubTimestamp":1723158394,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20240808:nFWN3JV1WK:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["XAO.AU","XJO.AU","BK7067","XKO.AU","CHM.AU"],"gpt_icon":0},{"id":"2453784098","title":"Chimeric Therapeutics Recruits First Patient in Cell Therapy Cancer Trial; Shares Rally 16%","url":"https://stock-news.laohu8.com/highlight/detail?id=2453784098","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2453784098?lang=en_us&edition=fundamental","pubTime":"2024-07-22 11:36","pubTimestamp":1721619393,"startTime":"0","endTime":"0","summary":"Chimeric Therapeutics recruited the first patient for its phase one/two trial for the cell therapy CDH17, according to a Monday filing with the Australian bourse.The trial aims to investigate the safety, response rate, and optimal dose of the cell therapy CDH17 in patients with colorectal and gastric cancers, as well as intestinal tumors, the cell therapy firm said in the filing.Shares of Chimeric Therapeutics rallied 16% in recent trade.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["CHM.AU","BK4139","LENZ","BK7067"],"gpt_icon":0},{"id":"2453784020","title":"Chimeric Therapeutics Recruits First Patient in Cell Therapy Cancer Trial; Shares Rally 16%","url":"https://stock-news.laohu8.com/highlight/detail?id=2453784020","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2453784020?lang=en_us&edition=fundamental","pubTime":"2024-07-22 11:36","pubTimestamp":1721619393,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_live","symbols":["BK4139","XKO.AU","XAO.AU","BK7067","LENZ","CHM.AU","XJO.AU"],"gpt_icon":0},{"id":"2453789574","title":"BUZZ-Australia Chimeric Therapeutics rises on first enrolment in cancer cell therapy trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2453789574","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2453789574?lang=en_us&edition=fundamental","pubTime":"2024-07-22 10:45","pubTimestamp":1721616342,"startTime":"0","endTime":"0","summary":"** Shares of Chimeric Therapeutics rise as much as 15.8% to A$0.022, hitting their highest level since May 27 ** Stock set for best day since March 1, if current gains hold ** Cell therapy co enrols first participant in Phase 1/2 multi-centre clinical trial for CHM CDH17 cell therapy ** CHM CD17 is in preclinical development, aims for complete eradication of tumours in seven types of cancer ** About 1.8 mln shares change hands, 1.3 times the 30-day average volume ** Stock down 45.7% this year, as of last close ","market":null,"thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7067","XJO.AU","XAO.AU","CHM.AU","XKO.AU"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.chimerictherapeutics.com","stockEarnings":[{"period":"1week","weight":0.3333},{"period":"1month","weight":-0.1429},{"period":"3month","weight":-0.2941},{"period":"6month","weight":-0.5385},{"period":"1year","weight":-0.5556},{"period":"ytd","weight":-0.6571}],"compareEarnings":[{"period":"1week","weight":-0.0176},{"period":"1month","weight":0.0132},{"period":"3month","weight":0.0363},{"period":"6month","weight":0.0312},{"period":"1year","weight":0.1798},{"period":"ytd","weight":0.1448}],"compareStock":{"symbol":"F100.AU","name":"BETASHARES FTSE 100 ETF"},"yearOnYearQuotes":[{"month":1,"riseRate":0,"avgChangeRate":-0.121995},{"month":2,"riseRate":0.25,"avgChangeRate":0.001919},{"month":3,"riseRate":0.25,"avgChangeRate":0.00794},{"month":4,"riseRate":0.25,"avgChangeRate":-0.185383},{"month":5,"riseRate":0.5,"avgChangeRate":-0.045768},{"month":6,"riseRate":0.75,"avgChangeRate":0.139489},{"month":7,"riseRate":0,"avgChangeRate":-0.08104},{"month":8,"riseRate":0,"avgChangeRate":-0.163624},{"month":9,"riseRate":0.25,"avgChangeRate":-0.086896},{"month":10,"riseRate":0.25,"avgChangeRate":0.0482},{"month":11,"riseRate":0.333333,"avgChangeRate":0.031162},{"month":12,"riseRate":0,"avgChangeRate":-0.176007}],"exchange":"ASX","name":"CHIMERIC THERAPEUTICS LTD","nameEN":"CHIMERIC THERAPEUTICS LTD"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.1","shortVersion":"4.29.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"CHIMERIC THERAPEUTICS LTD(CHM.AU),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest CHIMERIC THERAPEUTICS LTD(CHM.AU) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"CHIMERIC THERAPEUTICS LTD,CHM.AU,CHIMERIC THERAPEUTICS LTD股票,CHIMERIC THERAPEUTICS LTD股票老虎,CHIMERIC THERAPEUTICS LTD股票老虎国际,CHIMERIC THERAPEUTICS LTD行情,CHIMERIC THERAPEUTICS LTD股票行情,CHIMERIC THERAPEUTICS LTD股价,CHIMERIC THERAPEUTICS LTD股市,CHIMERIC THERAPEUTICS LTD股票价格,CHIMERIC THERAPEUTICS LTD股票交易,CHIMERIC THERAPEUTICS LTD股票购买,CHIMERIC THERAPEUTICS LTD股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"CHIMERIC THERAPEUTICS LTD(CHM.AU),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest CHIMERIC THERAPEUTICS LTD(CHM.AU) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}